Cleerly Stock
HealthTechLooking to sell Cleerly stock or options?
Cleerly has developed a healthcare platform that aims to establish a novel standard of care for coronary artery disease. This platform leverages a non-invasive, AI-fueled method that enhances comprehension of plaques and provides an exhaustive quantification and depiction of plaque accumulation in the coronary arteries. This empowers healthcare providers to significantly enhance the detection of patients at risk, enabling early treatment and prevention of heart attacks in a cost-efficient manner.
LRVHealth, American College of Cardiology Foundation, Cigna Ventures, Vensana Capital, Catalytic Impact Foundation, Highcroft Capital, Fidelity Management & Research, Piper Sandler, Impact Assets, Sands Capital, DigiTx Partners, Novartis, Pura Vida Investments, Presight Capital, Esplanade Healthtech Ventures, Double Point Ventures, Peter Thiel, Mirae Asset Capital, New Leaf Venture, T. Rowe Price Group, Breyer Capital, Gershon Capital, General Catalyst.